The property, 10,400 square feet of space at Newtown Commons West outside Philadelphia, will serve as corporate headquarters, a clinical research site and a physical therapy training center. The company plans to move in July 1.
“We are delighted with this move as it allows us to continue to build our clinical and commercialization infrastructure for our proprietary PoNS Therapy. We chose Newtown because it affords us access to a large pool of clinical and commercialization talent and its proximity to major international airports,” CEO Philippe Deschamps said in a press release.
In February, Helius said it closed an offering worth nearly $10 million (CAD $12.5 million) for the portable neurostimulation device it’s developing.
Helius said it plans to use the proceeds from the 6.6-million-share flotation to complete a trial of the PoNS therapy in treating mild to moderate brain injury and the launch of a new trial in multiple sclerosis and another in cognition.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.